Oncosil Medical (OSL) Short Interest
Oncosil Medical (ASX:OSL) had 0.00% of shares reported as short positions as of 24 Aug 2026, representing 66 shares. Oncosil Medical operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Oncosil Medical
Oncosil Medical is a medical device company focused on the development and commercialization of innovative cancer treatments. Their primary product, OncoSil, is a brachytherapy device containing radioactive phosphorus-32, designed for the treatment of locally advanced pancreatic cancer. The company aims to improve patient outcomes and quality of life through targeted radiation therapy.
Short position
Oncosil Medical (ASX:OSL) has 0.00% of its shares on issue reported as short positions as of 24 Aug 2026, or about 66 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.68% in December 2024. OSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4OSL intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Oncosil Medical
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OSL
Start a research thread or post the first pulse update